Table 2.
Univariate and multivariate analysis of predictors for roxadustat treatment failure in patients with renal anemia.
| Basic characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HRa | 95% CIb | P value | HR | 95% CI | P value | |
| Demographic data | ||||||
| Body mass index (< 25 kg/m2 vs. ≥ 25 kg/m2) | 0.89 | 0.73–1.73 | 0.583 | |||
| Smoking history (no vs. yes) | 1.08 | 0.51–1.7 | 0.802 | |||
| PD duration (vs. ≥ 1 year) | ||||||
| < 1 year | 1.22 | 0.56–2.66 | 0.621 | 1.10 | 0.50–2.40 | 0.821 |
| Initial PD catheter | 2.15 | 1.27–3.65 | 0.005 | 2.49 | 1.45–4.28 | 0.0009 |
| Laboratory tests | ||||||
| Reticulocyte (≤ 1.5% vs. > 1.5%) | 1.23 | 0.52–1.28 | 0.373 | |||
| Hemoglobin (< 100 g/L vs. ≥ 100 g/L) | 0.77 | 0.63–2.67 | 0.486 | |||
| Erythropoietin (vs. > 29 mIU/ml) | ||||||
| 4.3–29 mIU/ml | 0.92 | 0.50–1.27 | 0.718 | |||
| < 4.3 mIU/ml | 1.36 | 0.91–1.72 | 0.073 | |||
| Transferrin saturation (< 20% vs. ≥ 20%) | 0.84 | 0.78–1.79 | 0.423 | |||
| Serum ferritin (< 100 ug/L vs. ≥ 100 ug/L) | 0.74 | 0.84–2.18 | 0.210 | |||
| Serum transferrin (< 2 g/L vs. 2–3.6 g/L) | 1.45 | 0.46–1.03 | 0.071 | 0.68 | 0.46–1.02 | 0.065 |
| Blood total carbon dioxide (< 22 mmol/L vs. ≥ 22 mmol/L) | 0.73 | 0.92–2.04 | 0.116 | |||
| PLR (< 180 vs. ≥ 180) | 1.34 | 0.5–1.11 | 0.144 | |||
| NLR (< 3.1 vs. ≥ 3.1) | 1.38 | 0.47–1.12 | 0.150 | |||
| Serum phosphate (1.6–0.96 mmol/L vs. > 1.62 mmol/L) | 1.31 | 0.51–1.14 | 0.188 | |||
| Alkaline phosphatase(vs. > 185 U/L) | ||||||
| 47–185 U/L | 0.50 | 0.20–1.26 | 0.139 | |||
| < 47 U/L | 0.70 | 0.40–1.21 | 0.207 | |||
| BNP (5–100 pg/mL vs. > 100 pg/mL) | 0.76 | 0.87–1.97 | 0.191 | |||
| Albumin (< 40 ug/L vs. ≥ 40 ug/L) | 1.13 | 0.41–1.92 | 0.762 | |||
| Scr (44–106 umol/L vs. > 106 umol/L) | 1.00 | 0.37–2.68 | 0.998 | |||
| CRP (< 8 mg/L vs. ≥ 8 mg/L) | 0.93 | 0.71–1.65 | 0.719 | |||
| eGFR (< 90 ml/min/1.73–2 vs. ≥ 90 ml/min/1.73–2) | 0.00 | 0-Inf | 0.995 | |||
| TC(vs. > 5.72 mmol/L) | ||||||
| 2.9–5.72 mmol/L | 0.87 | 0.46–1.64 | 0.665 | |||
| < 2.9 mmol/L | 0.75 | 0.49–1.11 | 0.159 | |||
| TG(vs. > 1.7 mmol/L) | ||||||
| 0.56–1.7 mmol/L | 2.18 | 0.54–8.92 | 0.277 | |||
| < 1.7 mmol/L | 0.68 | 0.29–1.57 | 0.369 | |||
| LDL(vs. > 3.1 mmol/L) | ||||||
| 1.89–3.1 mmol/L | 0.88 | 0.57–1.34 | 0.537 | |||
| < 1.89 mmol/L | 0.87 | 0.62–1.22 | 0.416 | |||
| Comorbidities (no vs. yes) | ||||||
| Diabetes mellitus | 1.01 | 0.66–1.48 | 0.955 | |||
| Infection | 0.77 | 0.86–1.98 | 0.206 | |||
| Hypertension | 1.18 | 0.41–1.75 | 0.651 | |||
| Cardiovascular diseases | 1.65 | 0.4–0.92 | 0.019 | 0.63 | 0.40–0.97 | 0.038 |
| liver cirrhosis | 1.33 | 0.33–1.72 | 0.499 | |||
| Gastrointestinal bleeding | 0.79 | 1.46–3.45 | 0.648 | |||
| Combined medication (no vs. yes) | ||||||
| Iron agency | 1.05 | 0.64–1.43 | 0.814 | |||
| PHOSPHATE-Lowering agents | 1.02 | 0.67–1.46 | 0.937 | |||
| Stains | 0.57 | 1.02–3.01 | 0.041 | 1.63 | 0.91–2.92 | 0.097 |
HR hazard ratio, CI confidence interval, PD peritoneal dialysis, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratio, BNP brain natriuretic peptide, Scr Serum creatinine, CRP C-reactive protein, eGFR estimated glomerular filtration rate, TC total cholesterol, TG triglyceride, LDL low density lipoprotein cholesterol.